Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats Symptomatic GERD. Sold as Aciphex, Aciphex Sprinkle. Every FDA application for this active ingredient: 3 branded and 10 generic.
As of Nov 15, 2026, FDA lists 13 applications for Rabeprazole Sodium (sold as Aciphex, Aciphex Sprinkle), first approved Aug 19, 1999, with 3 new uses approved and 0 published complete response letters.
First approved: Aug 19, 1999
Applications: 13
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $26.3M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
ParietDrugs with a new dosage indicated for the treatment of reflux esophagitis. · Eisai Co., Ltd. · Sep 22, 2017
Pariet, new approvalA drug with a new additional indication and a new dosage in a newly-added dosage form, and a drug with a new additional indication and a new dosage for the… · Eisai Co., Ltd. · Dec 26, 2014
ParietDrugs with new dosages for the treatment of reflux esophagitis. · Eisai Co., Ltd. · Dec 21, 2010
ParietA drug with a new additional indication and a new dosage for the treatment of non-erosive reflux disease. · Eisai Co., Ltd. · Jun 18, 2010
Clinical Trials
21 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
